Piyasa açık· · GBp · Veriler gecikmeli olabilir
Fiyatlar gecikmeli olabilir ve yalnızca bilgilendirme amaçlıdır - yatırım tavsiyesi değildir.
Temettüler dahil toplam getiri.
Fiyatın 50 ve 200 günlük hareketli ortalamalara göre konumu.
Makkler Adil Değer, finansal sağlık skoru, analist görüşü, benzer şirketler ve MakklerAI.
Genus (LON:GNS) reported higher adjusted profit and cash generation for FY 2026, supported by growth in its porcine genetics business, efficiency gains in bovine genetics and contributions from joint ventures. The company also announced a £60 million share buyback and proposed a 10% increase in its
Genus has just seen its fair value estimate tweaked, with the price target adjusted from £31.63 to about £31.28 per share. This small move reflects a mix of optimism and caution in recent analyst commentary, where views on growth, execution risk, and required returns are being rebalanced. As you read on, you will see how these shifting assumptions shape the evolving Genus story and what to watch next in the narrative. Analyst Price Targets don't always capture the full story. Head over to our...
Genus has seen its modelled fair value move from £30.82 to £31.67, a small uplift that may still matter if you are tracking the shares closely. Analysts linking this £1.00 change to revised assumptions are effectively updating how they weigh Genus’ potential against execution risks, with bullish and cautious camps reading the same inputs in different ways. As you read on, you will see how these shifts fit into the broader analyst debate and what to watch as the narrative evolves. Analyst...
Üçüncü taraf yayıncıların bu şirket hakkındaki son başlıkları; Makkler'in kendi editoryal içeriğinden ayrı tutulur ve dış kaynağa yönlendirir. Başlıkların doğruluğu ilgili yayıncının sorumluluğundadır.